Cytokinetics, Inc. reported results from the 41-patient Phase II REDWOOD-HCM clinical trial on 19 July that appear to show better efficacy and improved safety with the cardiac myosin inhibitor CK-274 in the treatment of obstructive hypertrophic cardiomyopathy (oHCM) relative to mavacamten, a similar drug now owned by Bristol Myers Squibb Company that is under US Food and Drug Administration review with an approval decision expected in January.
Cytokinetics’ CK-274 Appears To Upstage BMS’s Newly Acquired Mavacamten
Phase III Trial To Start By Year’s End
The REDWOOD-HCM study showed early, sustained efficacy and no serious adverse events with a drug Cytokinetics designed to be superior to mavacamten, a drug it spun out via BMS-acquired MyoKardia.
More from Clinical Trials
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from R&D
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.